Clinical trials: Pharmacology, Clinical
Clostridium Difficile Infection
Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
Patients with confirmed C. difficile infection (CDI) who meet eligibility requirements will be invited to participate. All study patients must receive treatment for CDI with metronidazole or vancomycin.
- Trial name
- NCT01077245
- Testing
- MIYA-BM Fine Granules (CBM588)
- Sponsor
- Osel, Inc.
Hyperbilirubinemia
Safety and Pharmacology of Stanate
The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.
- Trial name
- NCT00115544
- Testing
- Stanate
- Where
- Vietnam
- Volunteers
- 55 people
- Sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Pharmacology, Clinical, Healthy
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
1. To evaluate the pharmacokinetics (PK) of pomalidomide administered with the CYP3A4/P-gp inhibitor ketoconazole compared with pomalidomide alone in healthy male subjects. 2.
- Trial name
- DDI (NCT01707407)
- Testing
- Pomalidomide, Ketoconazole, Fluvoxamine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Celgene
Schizophrenia
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
The purpose of this study is to determine the pharmacokinetics (PK), tolerability and safety of brexpiprazole LAI following a single administration in subjects with schizophrenia.
- Trial name
- NCT05119894
- Testing
- Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Clinical Pharmacology
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 15 mg in Japanese healthy…
- Trial name
- NCT04511637
- Testing
- Rivaroxaban (BAY 59-7939, Xarelto) in ODT form, Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
- Where
- 3 sites in Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer
This study will induce disuse atrophy through unilateral immobilization of the thigh and lower leg in healthy male volunteers to evaluate the PD of a single subcutaneous dose of GYM329 prior to or after unilateral thigh and lower…
- Trial name
- NCT04708847
- Testing
- GYM329
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chugai Pharmaceutical
Healthy
Single Dose Phase I Study of FYU-981
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of FYU-981 administered orally to healthy male adults in fasted and fed conditions.
- Trial name
- NCT02348307
- Testing
- FYU-981, (Oral single dosing)
- Where
- Japan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Fuji Yakuhin Co., Ltd.
Chronic Hepatitis C
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
The purposes of this study are: to determine the safety and tolerability of multiple doses of A-831 at various doses to determine how multiple doses of A-831 are distributed through the bloodstream to determine if A-831 reduces…
- Trial name
- CP104 (NCT00522808)
- Testing
- A-831
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Arrow Therapeutics